

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 7942503-00009 Date of last issue: 28.09.2024 Date of first issue: 19.03.2021

SECTION 1. IDENTIFICATION

Product identifier : Oxfendazole / Oxclozanide Formulation

Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530
Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 2 (Central nervous system)
single exposure (Oral)

Specific target organ toxicity - : Category 2 (Liver, Testis, Brain)
repeated exposure

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360FD May damage fertility. May damage the unborn child.
H371 May cause damage to organs (Central nervous system) if swallowed.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 7942503-00009	Date of last issue: 28.09.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

H373 May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary Statements	:	Prevention: P201 Obtain special instructions before use. P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
		Response: P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor. P391 Collect spillage.
		Storage: P405 Store locked up.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Oxclozanide	2277-92-1	Acute Tox. (Oral), 5 Repr., 2 STOT SE, (Oral)(Central nervous system) , 2 STOT RE, (Brain, Liver) , 2 Aquatic Acute, 1 Aquatic Chronic, 1	>= 30 -< 50
oxfendazole	53716-50-0	Repr., 1B STOT RE, (Liver, Testis) , 2 Aquatic Acute, 1 Aquatic Chronic, 1	>= 20 -< 25
Starch, oxidized	65996-62-5		>= 10 -< 20
Magnesium stearate	557-04-0		>= 1 -< 5

SECTION 4. FIRST AID MEASURES

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 7942503-00009	Date of last issue: 28.09.2024 Date of first issue: 19.03.2021
General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.		
If inhaled	: If inhaled, remove to fresh air. Get medical attention.		
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.		
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.		
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.		
Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May damage fertility. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.		
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).		
Notes to physician	: Treat symptomatically and supportively.		

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Chlorine compounds Nitrogen oxides (NO _x) Metal oxides Oxides of phosphorus
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do

Oxfendazole / Oxclozanide FormulationVersion
6.0Revision Date:
14.04.2025SDS Number:
7942503-00009Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 7942503-00009	Date of last issue: 28.09.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

Hygiene measures	<p>Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.</p> <p>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</p>
Conditions for safe storage	<p>Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.</p>
Materials to avoid	<p>Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases</p>

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Oxclozanide	2277-92-1	TWA	0.4 mg/m ³ (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Starch, oxidized	65996-62-5	TWA (inhalable dust)	0,5 mg/m ³	ACGIH
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures	<p>All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of</p>
----------------------	--

Oxfendazole / Oxclozanide FormulationVersion
6.0Revision Date:
14.04.2025SDS Number:
7942503-00009Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	
Hand protection	: Particulates type
Material	: Chemical-resistant gloves
Remarks	
Eye protection	: Consider double gloving. : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	: powder
Color	: white to off-white, light cream, cream
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: Not applicable
Upper explosion limit / Upper flammability limit	: No data available

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 7942503-00009 Date of last issue: 28.09.2024 Date of first issue: 19.03.2021

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : 0,88 g/cm³

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 7942503-00009 Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Product:

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Components:

Oxclozanide:

Acute oral toxicity : LD50 (Rat): 3.519 mg/kg
Target Organs: Central nervous system

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg
Application Route: Intravenous

oxfendazole:

Acute oral toxicity : LD50 (Rat): > 6.000 mg/kg
LD50 (Dog): 1.600 mg/kg
LD50 (sheep): 250 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Oxclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rabbit
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Oxfendazole / Oxclozanide FormulationVersion
6.0Revision Date:
14.04.2025SDS Number:
7942503-00009Date of last issue: 28.09.2024
Date of first issue: 19.03.2021**Components:****Oxclozanide:**

Remarks	:	Not classified due to lack of data.
---------	---	-------------------------------------

oxfendazole:

Species	:	Rabbit
Result	:	No eye irritation

Magnesium stearate:

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Oxclozanide:**

Routes of exposure	:	Dermal
Remarks	:	Not classified due to lack of data.

Magnesium stearate:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**Oxclozanide:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
		Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	:	Test Type: Micronucleus test

Oxfendazole / Oxclozanide Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 7942503-00009	Date of last issue: 28.09.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

	Species: Mouse Application Route: Oral Result: negative
	Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.
oxfendazole:	
Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Oral Result: positive
Magnesium stearate:	
Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials
	Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials
	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Oxclozanide:**

	Remarks	: Not classified due to lack of data.
--	---------	---------------------------------------

oxfendazole:

	Species	: Rat
	Application Route	: Oral
	Exposure time	: 1 Years
	Symptoms	: No adverse effects.
	Target Organs	: Liver

Oxfendazole / Oxclozanide Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 7942503-00009	Date of last issue: 28.09.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
Symptoms	:	No adverse effects.
Target Organs	:	Liver

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:**Oxclozanide:**

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat, male and female Application Route: Oral General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal and postnatal development. Result: No effects on fertility.
	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal and postnatal development. Result: No effects on fertility.
	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight Result: No fetotoxicity., No teratogenic effects.
	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity., No teratogenic effects., No effects on fertility.
Effects on fetal development	: Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No fetotoxicity., No teratogenic effects.
	Test Type: Development Species: Rat Application Route: Oral General Toxicity Maternal: LOAEL: 100 mg/kg body weight Result: No fetotoxicity., No teratogenic effects.
	Test Type: Development

Oxfendazole / Oxclozanide FormulationVersion
6.0Revision Date:
14.04.2025SDS Number:
7942503-00009Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

	Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 32 mg/kg body weight Result: Fetotoxicity., Skeletal malformations.
Reproductive toxicity - Assessment	: Suspected of damaging the unborn child.
oxfendazole:	
Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: NOAEL: 17 mg/kg body weight Target Organs: Testes Result: Effects on fertility.
	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: NOAEL: 0,9 mg/kg body weight Target Organs: Liver Result: No effects on fertility.
	Test Type: Fertility Species: Mouse Application Route: Oral Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight Target Organs: Testes Result: Effects on fertility.
Effects on fetal development	: Test Type: Embryo-fetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Fetal effects.
	Test Type: Embryo-fetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Embryo-fetal toxicity.
	Test Type: Embryo-fetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-fetal toxicity., Fetal abnormalities.
	Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 0,625 mg/kg body weight
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of

Oxfendazole / Oxclozanide Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 7942503-00009	Date of last issue: 28.09.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

adverse effects on development, based on animal experiments.

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:**Oxclozanide:**

Routes of exposure : Oral
Target Organs : Central nervous system
Assessment : May cause damage to organs.

STOT-repeated exposure

May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

Components:**Oxclozanide:**

Target Organs : Brain, Liver
Assessment : May cause damage to organs through prolonged or repeated exposure.

oxfendazole:

Routes of exposure : Oral
Target Organs : Liver, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Oxclozanide:**

Species : Rat
NOAEL : 9 mg/kg
LOAEL : 44,5 mg/kg
Application Route : Oral

Oxfendazole / Oxclozanide Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 7942503-00009 Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Exposure time	:	3 Months
Target Organs	:	Brain, Liver, spleen, Adrenal gland
Symptoms	:	Liver effects
Species	:	Dog
NOAEL	:	5 mg/kg
LOAEL	:	25 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver
Symptoms	:	blood effects, alteration in liver enzymes

oxfendazole:

Species	:	Rat
NOAEL	:	11 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Target Organs	:	Blood, Liver, Testis
Species	:	Rat
NOAEL	:	3,8 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver, Testis
Species	:	Mouse
NOAEL	:	750 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Target Organs	:	Liver
Species	:	Mouse
NOAEL	:	37,5 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver
Species	:	Dog
NOAEL	:	6 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Remarks	:	No significant adverse effects were reported
Species	:	Dog
NOAEL	:	11 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Target Organs	:	Lymph nodes, thymus gland
Species	:	Dog
NOAEL	:	13,5 mg/kg
Application Route	:	Oral
Exposure time	:	12 Months
Target Organs	:	Liver

Oxfendazole / Oxclozanide FormulationVersion
6.0Revision Date:
14.04.2025SDS Number:
7942503-00009Date of last issue: 28.09.2024
Date of first issue: 19.03.2021**Starch, oxidized:**

Species	:	Rat
NOAEL	:	22.500 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

Magnesium stearate:

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:**Oxclozanide:**

Not applicable

Experience with human exposure**Components:****Oxclozanide:**

Ingestion	:	Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression
-----------	---	--

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Oxclozanide:**

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0,69 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
---	---	--

M-Factor (Acute aquatic toxicity)	:	1
-----------------------------------	---	---

M-Factor (Chronic aquatic toxicity)	:	1
-------------------------------------	---	---

oxfendazole:

Toxicity to fish	:	LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2,7 mg/l Exposure time: 96 h
------------------	---	--

LC50 (Oncorhynchus mykiss (rainbow trout)): > 2,5 mg/l Exposure time: 96 h

SAFETY DATA SHEET



Oxfendazole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024
6.0 14.04.2025 7942503-00009 Date of first issue: 19.03.2021

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0,059 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	10
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0,023 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	:	1
Magnesium stearate:		
Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility.
		NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 7942503-00009 Date of last issue: 28.09.2024 Date of first issue: 19.03.2021

II

Persistence and degradability

Components:

Oxclozanide:

Stability in water : Hydrolysis: 50 %(156 d)
Method: OECD Test Guideline 111

oxfendazole:

Stability in water : Hydrolysis: < 5 %(4 d)

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Oxclozanide:

Partition coefficient: n-octanol/water : log Pow: 3,99
pH: 7
Method: OECD Test Guideline 107

oxfendazole:

Partition coefficient: n-octanol/water : log Pow: 1,95

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Oxclozanide:

Distribution among environmental compartments : log Koc: 4,83
Method: OECD Test Guideline 106

oxfendazole:

Distribution among environmental compartments : log Koc: 3,2

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 7942503-00009 Date of last issue: 28.09.2024 Date of first issue: 19.03.2021

Contaminated packaging : Dispose of in accordance with local regulations.
Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(oxfendazole, oxclozanide)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(oxfendazole, Oxclozanide)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(oxfendazole, Oxclozanide)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

ANTT

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(oxfendazole, oxclozanide)
Class : 9
Packing group : III
Labels : 9
Hazard Identification Number : 90

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 7942503-00009 Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 14.04.2025
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory con-

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version
6.0

Revision Date:
14.04.2025

SDS Number:
7942503-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

centration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8